{"disease":{"id":"kidney-carcinoma","name":"kidney carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00898365","title":"Study of Kidney Tumors in Younger Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8000,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT02465060","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6452,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00001238","title":"Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07117227","title":"Validation of RCC Predicting Model With Emulated-target Trial","phase":"","overall_status":"RECRUITING","enrollment_count":4700,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT00340457","title":"Case-Control Study of Renal Cell Cancer Among Caucasions and African Americans in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":2424,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04955808","title":"Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery","phase":"","overall_status":"SUSPENDED","enrollment_count":2400,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05334069","title":"Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT06364631","title":"CARE1 Pragmatic Clinical Trial","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1250,"lead_sponsor_name":"Gustave Roussy, Cancer Campus, Grand Paris","has_results":false},{"nct_id":"NCT03793166","title":"Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1175,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07004426","title":"Symptomatic and Incidental RCC Detection","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Charles University, Czech Republic","has_results":false},{"nct_id":"NCT03896958","title":"The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"SpeciCare","has_results":false},{"nct_id":"NCT03455452","title":"Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT04623502","title":"An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy","phase":"NA","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT06339138","title":"Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":589,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03981497","title":"Microwave Ablation for Treatment of Small Renal Tumors and Primary and Secondary Liver Neoplasms","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Francesco De Cobelli","has_results":false},{"nct_id":"NCT05534854","title":"Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT06456411","title":"Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain Management in Patients With Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":410,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT03977571","title":"Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Niels Fristrup","has_results":false},{"nct_id":"NCT03866382","title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":314,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05729763","title":"Three-dimensional Virtual Imaging to Improve the Accuracy of Standard CT-based Nephrometric Scores: a Prospective Multicentric Observational Study","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"San Luigi Gonzaga Hospital","has_results":false},{"nct_id":"NCT07485114","title":"Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Daniel Keizman","has_results":false},{"nct_id":"NCT02601950","title":"A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":267,"lead_sponsor_name":"Epizyme, Inc.","has_results":true},{"nct_id":"NCT06726421","title":"Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":252,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06899789","title":"Long-term Follow-up of Checkpoint Inhibitors-induced Ileo-colitis","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT06682793","title":"A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"A2 Biotherapeutics Inc.","has_results":false},{"nct_id":"NCT05796973","title":"Measuring Oncological Value of Exercise and Statin","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Tampere University Hospital","has_results":false},{"nct_id":"NCT06536439","title":"Planning Operative Strategy Using a Digital Renal Artery Clamping Tool","phase":"NA","overall_status":"RECRUITING","enrollment_count":235,"lead_sponsor_name":"University Hospital, Ghent","has_results":false},{"nct_id":"NCT05519878","title":"Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers","phase":"NA","overall_status":"RECRUITING","enrollment_count":224,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT04659343","title":"TDM for Optimized Outcome in Patients With mRCC.","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Niels Fristrup","has_results":false},{"nct_id":"NCT04802876","title":"Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":184,"lead_sponsor_name":"SOLTI Breast Cancer Research Group","has_results":false},{"nct_id":"NCT03534141","title":"Mild Hypothermia and Acute Kidney Injury in Liver Transplantation","phase":"NA","overall_status":"TERMINATED","enrollment_count":175,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT05135832","title":"Patient Reported Outcomes by Patients With Metastatic Renal Cell Carcinoma","phase":"NA","overall_status":"UNKNOWN","enrollment_count":174,"lead_sponsor_name":"Herlev and Gentofte Hospital","has_results":false},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT01835158","title":"Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":157,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02721732","title":"Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":157,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02496208","title":"Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":152,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06789224","title":"Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab Device","phase":"NA","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"Lindis Bloodcare GmbH","has_results":false},{"nct_id":"NCT04071223","title":"Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":134,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02974738","title":"A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":false},{"nct_id":"NCT05119335","title":"A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":120,"lead_sponsor_name":"NiKang Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03634540","title":"A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":118,"lead_sponsor_name":"Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":false},{"nct_id":"NCT02293980","title":"A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":110,"lead_sponsor_name":"Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":false},{"nct_id":"NCT02867592","title":"Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":109,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02210117","title":"Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery","phase":"EARLY_PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":104,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02118337","title":"A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":97,"lead_sponsor_name":"MedImmune LLC","has_results":true},{"nct_id":"NCT03334344","title":"Using Virtual Reality (VR) Models for Preoperative Planning","phase":"NA","overall_status":"COMPLETED","enrollment_count":92,"lead_sponsor_name":"Ceevra, Inc.","has_results":true},{"nct_id":"NCT05286801","title":"Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":86,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06211790","title":"Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":66,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04467021","title":"Cancer and Blood Pressure Management, CARISMA Study","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":61,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT06444815","title":"A Study of VET3-TGI in Patients With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"KaliVir Immunotherapeutics","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}